Axa S.A. Genmab A/S Transaction History
Axa S.A.
- $32.8 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding GMAB
# of Institutions
241Shares Held
47.6MCall Options Held
31.3KPut Options Held
38.7K-
Alliancebernstein L.P. New York, NY15.3MShares$384 Million0.17% of portfolio
-
Black Rock Inc. New York, NY5.07MShares$127 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA4.37MShares$110 Million0.03% of portfolio
-
Harding Loevner LP Bridgewater, NJ3.29MShares$82.9 Million0.63% of portfolio
-
Wellington Management Group LLP Boston, MA2.33MShares$58.6 Million0.01% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $16.6B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...